Wells Fargo & Company Calliditas Therapeutics Ab Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CALT
# of Institutions
23Shares Held
843KCall Options Held
8.5KPut Options Held
26.6K-
Bvf Inc San Francisco, CA750KShares$30 Million0.89% of portfolio
-
Ironwood Investment Management LLC Boston, MA25.6KShares$1.03 Million0.56% of portfolio
-
Optiver Holding B.V. Amsterdam, P722.3KShares$893,4400.02% of portfolio
-
Crossmark Global Holdings, Inc.16.1KShares$644,6800.01% of portfolio
-
Ubs Group Ag10.8KShares$430,2400.0% of portfolio
About Calliditas Therapeutics AB
- Ticker CALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,624,800
- Market Cap $1.06B
- Description
- Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...